Jaguar Health, Inc.
Registration link for webcast appears below
Company plans to file Q2 2021 10-Q on August 13, 2021
SAN FRANCISCO, CA / ACCESSWIRE / August 10, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that the Company investor webcast scheduled for Friday, August 13, 2021 will take place at 8:00 a.m. Eastern Time instead of 8:30 a.m.
Participation Instructions for Webcast
When: Friday, August 13, 2021 at 8:00 AM Eastern Time
Participant Registration & Access Link: Click Here
About Jaguar Health, Inc., Napo Pharmaceuticals, Inc. & Napo EU S.p.A.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Napo Pharmaceuticals' wholly owned Italian subsidiary, Napo EU S.p.A., focuses on expanding crofelemer access in Europe and is the named target of Dragon SPAC S.p.A.
For more information about Jaguar, please visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo EU, visit www.napoeu.com.
About Mytesi®
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." These include statements regarding the Company's expectation that an investor webcast will take place August 13, 2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
CONTACT:
Peter Hodge
Jaguar Health, Inc.
phodge@jaguar.health
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View source version on accesswire.com:
https://www.accesswire.com/659222/Jaguar-Health-Announces-Time-Change-for-Friday-August-13th-Investor-Webcast-to-800-AM-Eastern-Time
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Compliance Couture: How SMX and CETI are Changing the Rules for Fashion Sustainability (NASDAQ: SMX)15.10.2025 19:10:00 CEST | Press release
NEW YORK, NY, NY / ACCESS Newswire / October 15, 2025 / Global fashion brands require a single, essential ingredient to thrive: trust. Trust that its product is genuine, trust that the craftsmanship is authentic, and trust that the values behind the brand align with the ones it promotes. From Paris ateliers to fast-fashion retailers, every label's reputation depends on that same promise of quality, consistency, and credibility. But the world has changed. Supply chains have gone global. Sustainability has become a shareholder demand. And the old way of proving trust - through reputation alone - no longer cuts it. Today, trust must be earned through evidence. That's where SMX (NASDAQ:SMX) and CETI, the European Center for Innovative Textiles, come in. Together, they've created something fashion has needed for years: proof. Their industrial-scale collaboration embeds molecular-level traceability directly into textile fibers, giving every material its own unbreakable digital fingerprint. I
Matters.AI Announces $6.25 Million Funding to Launch the First AI Security Engineer That Keeps Enterprise Data Security on Autopilot15.10.2025 15:00:00 CEST | Press release
Matter.AI's autonomous system functions like an AI security engineer, understanding context, monitoring behavior, and protecting sensitive data SAN FRANCISCO, CA / ACCESS Newswire / October 15, 2025 / Matters.AI, an AI-native data security company, today announced $6.25 million in funding to pioneer a new class of data protection system, the AI Security Engineer. Funding consists of a $4.75 million Seed Round, co-led by Kalaari Capital and Endiya Partners, with participation from Better Capital, Carya Venture Partners, and leading cybersecurity angels, and an earlier $1.5 million pre-Seed Round led by Better Capital and Carya Venture Partners. The raise will fuel research and development in predictive defense, a US expansion, and scaling engineering to meet enterprise demand.Keshav Murthy, CEO & Co-Founder and Harsh Sahu, CTO & Co-Founder, Matters.AI Matters.AI is designed to function like an AI security engineer, giving enterprises one autonomous system that can see, understand, and p
Camino to Commence Drilling at its Los Chapitos Copper Project in Peru; Peru's Ministry of Energy and Mines Names Los Chapitos Among Top 15 Priority Exploration Projects15.10.2025 12:00:00 CEST | Press release
VANCOUVER, BC, AB / ACCESS Newswire / October 15, 2025 / Camino Minerals Corporation (TSXV:COR)(OTCID:CAMZF) ("Camino" or the "Company") is pleased to announce the mobilization of drilling equipment to commence the discovery drilling campaign at its Los Chapitos copper project in Peru ("Los Chapitos" or the "Project"). The 2025 exploration campaign with Camino's partner, Nittetsu Mining Co., Ltd. ("Nittetsu"), resulted in the identification of several prospective drilling targets. The drilling campaign will focus on two main objectives: discovering new copper-silver deposits in newly identified and undrilled targets, such as Mirador, Piloto, Maqui, and Sombrero Blanco, where notable copper occurrences have been found with high copper and silver values according to geochemical results of rocks in trenches, and extending known mineralization in previously drilled Adriana, Lourdes, and Katty (Enjambre) zones. Highlights: The latest results of trenching at the targets to be drilled showe
GoodData Reports Record Q3 Growth as It Expands AI Leadership15.10.2025 10:00:00 CEST | Press release
SAN FRANCISCO, CA, CA / ACCESS Newswire / October 15, 2025 / GoodData, a leading analytics and data intelligence company, today announced record Q3 results driven by its strongest net new sales ever, the acquisition of Understand Labs, and the launch of its new Full-Stack Intelligence Platform. The quarter underscored the company's accelerating enterprise adoption, growing international footprint, and continued investment in AI innovation. Business highlights GoodData's momentum continued to build in Q3, delivering its best-ever net new annual recurring revenue (ARR) performance. Enterprise engagement was a key driver of this success, with 90% of enterprise opportunities now progressing toward AI and agentic deployments. GoodData's acquisition of Understand Labs, a leader in semantic AI and natural language processing, further strengthened its AI-native capabilities. The addition of Understand Labs' technology will enhance the intelligence of GoodData's platform, enabling more natural,
Graid Technology Announces Strategic License Agreement With Intel Corporation to Accelerate RAID Innovation14.10.2025 18:00:00 CEST | Press release
SANTA CLARA, CALIFORNIA / ACCESS Newswire / October 14, 2025 / Graid Technology announced an agreement with Intel Corporation to enter into a license agreement granting Graid Technology the rights to develop, market, sell, and support Intel® Virtual RAID on CPU (Intel® VROC) globally. This strategic agreement is expected to accelerate innovation in the enterprise RAID market and deliver transformative outcomes for data center customers worldwide.Graid Technology and Intel Announce Strategic License Agreement In today's digital economy, data is the most valuable asset for every organization, and ensuring it is both resilient and readily available is critical to unlocking its full value. Through this agreement, Graid Technology will combine the proven enterprise performance of Intel® VROC with the breakthrough innovation of its own SupremeRAID™ portfolio, the industry's first GPU-based RAID architecture for high-performance workloads such as AI and HPC. By bringing together CPU-based and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom